Avandia (Avandia), Roglit (Roglit).
Oral hypoglycemic drug from the group of thiazolidinediones. Increases insulin sensitivity of adipose tissue, skeletal muscle and liver tissue. Reduces the glucose, insulin and free fatty acids in the blood. Preserves the function of P-cells, increases the mass of pancreatic islets and the content of insulin, prevents the development of severe hyperglycemia.
Does not stimulate the secretion of insulin and does not cause hypoglycemia. Slows the development of renal dysfunction and systolic arterial hypertension. Has a synergistic effect in combination with derivatives of sulfonylurea and metformin.
The dose of the drug and the regimen are set individually. The daily dose is taken in 1-2 divided doses, regardless of the meal.
For adults, the recommended initial dose is 4 mg / day. If necessary, according to the scheme of treatment, the dose can be increased to 8 mg / day.
From the side of metabolism: minor hypercholesterolemia, edema.
From the hemopoietic system: rarely – anemia.
From the side of the cardiovascular system: peripheral edema, heart failure (especially in patients of older age with a prolonged course of diabetes and receiving rosiglitazone at a dose of 8 mg / day); Rarely congestive heart failure and pulmonary edema.
On the part of the digestive system: rarely – increased activity of liver enzymes (causality is not proven).